U.S. drugmaker Pfizer could work its connections within President Donald Trump’s administration to try to thwart Novo Nordisk’s surprise rival bid to acquire U.S. obesity biotech firm Metsera, analysts, investors and lawyers said. Danish obesity and diabetes drug giant Novo said on Thursday it had bested Pfizer’s already agreed-upon deal, kicking off a fight for advantage in the market analysts forecast will grow to $150 billion. The next step is Pfizer’s, which has four business days to make a counteroffer, Metsera said, describing Novo’s bid as “superior.”
Read the full article: Pfizer Could Hold a Trump Card in Its Bid for Metsera //
Source: https://www.reuters.com/legal/litigation/pfizer-could-hold-trump-card-its-bid-metsera-2025-10-31/